After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of BridgeBio Pharma Inc is $6.89B. A total of 1.71 million shares were traded on the day, compared to an average of 2.67M shares.
In the most recent transaction, STEPHENSON BRIAN C sold 4,148 shares of BBIO for 36.16 per share on Feb 19 ’25. After the transaction, the Secretary, Treasurer & CFO now owns 102,464 company shares. In a previous transaction on Feb 19 ’25, Kumar Neil sold 31,543 shares at 36.14 per share. BBIO shares that Chief Executive Officer owns now total 211,718.
Among the insiders who bought shares, NEIL KUMAR acquired of 31,543 shares on Feb 19 ’25 at a per-share price of $35.49. In another insider transaction, BRIAN STEPHENSON bought 4,148 shares at $35.49 per share on Feb 19 ’25.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, BBIO has a high of $39.47 and a low of $21.62.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BBIO’s latest balance sheet shows that the firm has $836.66M in Cash & Short Term Investments as of fiscal 2021. There were $1.73B in debt and $135.07M in liabilities at the time. Its Book Value Per Share was -$7.72, while its Total Shareholder’s Equity was -$865.58M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BBIO is Buy with a score of 4.75.
